Eyenovia Inc
NASDAQ:EYEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Eyenovia Inc
Operating Income
Eyenovia Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eyenovia Inc
NASDAQ:EYEN
|
Operating Income
-$30.3m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$26.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$16.9B
|
CAGR 3-Years
14%
|
CAGR 5-Years
23%
|
CAGR 10-Years
23%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$19.9B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$26.8B
|
CAGR 3-Years
10%
|
CAGR 5-Years
20%
|
CAGR 10-Years
12%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$29.7B
|
CAGR 3-Years
53%
|
CAGR 5-Years
34%
|
CAGR 10-Years
24%
|
|
Eyenovia Inc
Glance View
Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company is headquartered in New York City, New York and currently employs 43 full-time employees. The company went IPO on 2018-01-25. The firm is developing a pipeline of therapeutics based on its microdose array print (MAP) platform technology. Its pipeline is focused on the late-stage development of therapeutic indications for pediatric patients with progressive myopia in the United States and patients with age-related near vision impairment, or presbyopia indications. The firm is also developing the microdose fixed combination ophthalmic pharmaceutical for mydriasis. The firm's product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, an ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation).
See Also
What is Eyenovia Inc's Operating Income?
Operating Income
-30.3m
USD
Based on the financial report for Mar 31, 2025, Eyenovia Inc's Operating Income amounts to -30.3m USD.
What is Eyenovia Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-8%
Over the last year, the Operating Income growth was 0%. The average annual Operating Income growth rates for Eyenovia Inc have been -28% over the past three years , -8% over the past five years .
